Fresenius Medical Care AG & Co. (FMS)
(Delayed Data from NYSE)
$18.38 USD
+0.13 (0.71%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $18.39 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Fresenius (FMS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$18.07 | $22.00 | $15.00 | -0.99% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Fresenius comes to $18.07. The forecasts range from a low of $15.00 to a high of $22.00. The average price target represents a decline of 0.99% from the last closing price of $18.25.
Analyst Price Targets (3 )
Broker Rating
Fresenius currently has an average brokerage recommendation (ABR) of 3.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, one is Strong Buy, representing 10% of all recommendations. A month ago, Strong Buy represented 20%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 6 | 5 | 5 | 5 |
Sell | 2 | 2 | 2 | 2 | 2 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 3.20 | 3.20 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | Not Identified | Not Identified | Moderate Sell | Moderate Sell |
7/30/2024 | Truist Securities | David S Macdonald | Hold | Hold |
5/5/2024 | Not Identified | Not Identified | Hold | Hold |
3/29/2024 | Goldman Sachs | Richard Felton | Strong Buy | Strong Buy |
2/21/2024 | UBS | Graham Doyle | Hold | Hold |
1/4/2024 | Not Identified | Not Identified | Hold | Hold |
11/24/2023 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.20 |
ABR (Last week) | 3.20 |
# of Recs in ABR | 10 |
Average Target Price | $18.17 |
LT Growth Rate | 12.40% |
Industry | Medical - Instruments |
Industry Rank by ABR | 90 of 253 |
Current Quarter EPS Est: | 0.42 |